DeepMed Research

Sumitomo Pharma Switzerland GmbH

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Phase 3

Recruiting

Conditions: Uterine Fibroids
Endometriosis

Interventions: Drug: Relugolix Combination Tablet

First Posted Date: 2023-05-17

Last Posted Date: 2024-03-15

Lead Sponsor: Sumitomo Pharma Switzerland GmbH

Target Recruit Count: 1000

Registration Number: NCT05862272

Locations: 🇺🇸
Mesa, Mesa, Arizona, United States
🇺🇸
Erie, Erie, Pennsylvania, United States
🇺🇸
Meridian, Meridian, Idaho, United States

and more 79 locations

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

Not yet recruiting

Conditions: Pregnancy Related
Pregnancy Complications
Pregnancy, High Risk

Interventions: Drug: Relugolix + Estradiol + Norethindrone Acetate

First Posted Date: 2023-02-22

Last Posted Date: 2024-03-08

Lead Sponsor: Sumitomo Pharma Switzerland GmbH

Target Recruit Count: 530

Registration Number: NCT05739136

Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

Recruiting

Conditions: Pregnancy, High Risk
Pregnancy Complications
Pregnancy Related

Interventions: Drug: Relugolix-Containing Product

First Posted Date: 2023-02-22

Last Posted Date: 2024-05-16

Lead Sponsor: Sumitomo Pharma Switzerland GmbH

Target Recruit Count: 728

Registration Number: NCT05739123

Locations: 🇺🇸
PPD, Wilmington, North Carolina, United States

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Relugolix
Drug: Leuprolide Acetate

First Posted Date: 2022-11-04

Last Posted Date: 2025-04-04

Lead Sponsor: Sumitomo Pharma Switzerland GmbH

Target Recruit Count: 387

Registration Number: NCT05605964

Locations: 🇺🇸
Central Ohio Urology Group Satellite, Gahanna, Ohio, United States
🇺🇸
Central Ohio Urology Group, Gahanna, Ohio, United States
🇺🇸
Urology Associates of Mobile, Mobile, Alabama, United States

and more 98 locations

A Multi-Center, Prospective, Observational Study of Patients Being Treated with ORGOVYX

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Relugolix

First Posted Date: 2022-07-20

Last Posted Date: 2024-11-26

Lead Sponsor: Sumitomo Pharma Switzerland GmbH

Target Recruit Count: 999

Registration Number: NCT05467176

Locations: 🇺🇸
University of Tennessee Medical Center, Knoxville, Tennessee, United States
🇺🇸
MD Anderson, Houston, Texas, United States
🇺🇸
Ascend Pharma Holdings, Houston, Texas, United States

and more 92 locations

Congenital Athymia Patient Registry

Recruiting

Conditions: Congenital Athymia
Complete DiGeorge Syndrome
Complete DiGeorge Anomaly

Interventions: Biological: Cultured Thymus Tissue

First Posted Date: 2022-04-15

Last Posted Date: 2024-03-15

Lead Sponsor: Sumitomo Pharma Switzerland GmbH

Target Recruit Count: 75

Registration Number: NCT05329935

Locations: 🇺🇸
Duke University School of Medicine, Durham, North Carolina, United States

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

Phase 3

Active, not recruiting

Conditions: Contraception

Interventions: Drug: Relugolix Combination Therapy

First Posted Date: 2021-02-16

Last Posted Date: 2025-05-18

Lead Sponsor: Sumitomo Pharma Switzerland GmbH

Target Recruit Count: 1020

Registration Number: NCT04756037

Locations: 🇺🇸
Encinitas, Encinitas, California, United States
🇺🇸
Gardena, Gardena, California, United States
🇺🇸
Burbank, Burbank, California, United States

and more 90 locations

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Metastatic Castration-Resistant Prostate Cancer
Non-Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Sensitive Prostate Cancer

Interventions: Drug: Relugolix
Drug: Abiraterone
Drug: Apalutamide
Drug: Prednisone
Drug: Docetaxel
Drug: Methylprednisolone

First Posted Date: 2020-12-14

Last Posted Date: 2024-12-18

Lead Sponsor: Sumitomo Pharma Switzerland GmbH

Target Recruit Count: 48

Registration Number: NCT04666129

Locations: 🇺🇸
Clinical Research Alliance, Inc., Westbury, New York, United States
🇺🇸
Arkansas Urology, Little Rock, Arkansas, United States
🇺🇸
Alliance Urology, Greensboro, North Carolina, United States

and more 13 locations

Farber Disease Natural History Study

Completed

Conditions: Farber Disease
Farber Lipogranulomatosis
ASAH1 Mutation
Farber's Disease
N-Laurylsphingosine Deacylase Deficiency
Acid Ceramidase Deficiency
Ceramidase Deficiency

First Posted Date: 2017-07-31

Last Posted Date: 2020-01-18

Lead Sponsor: Sumitomo Pharma Switzerland GmbH

Target Recruit Count: 45

Registration Number: NCT03233841

Locations: 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸
Children's National Health System, Washington, District of Columbia, United States
🇦🇷
Hospital de Niños de la Santisima Trinidad, Córdoba, CP, Argentina

and more 12 locations

Expanded Access Protocol Thymus Transplantation

Phase 4

Completed

Conditions: Immunoreconstitution
Poor Thymic Function
Immunodeficiency
Athymia
Thymus Transplantation
Low T Cell Numbers

Interventions: Biological: Cultured Thymus Tissue
Procedure: Blood Draw
Drug: Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus

First Posted Date: 2014-10-24

Last Posted Date: 2025-01-16

Lead Sponsor: Sumitomo Pharma Switzerland GmbH

Target Recruit Count: 11

Registration Number: NCT02274662

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy